States Develop Varied Regulatory Approaches to Control Potent Kratom Derivatives

As concentrated kratom derivatives, particularly 7-hydroxymitragynine known as 7-OH, become more prevalent in the marketplace, states are taking divergent regulatory approaches to address concerns about increasingly potent products while potentially preserving access to traditional kratom leaf. At least 31 states currently regulate kratom through various mechanisms including bans, age restrictions, and labeling requirements, with 36 states introducing legislation during recent legislative sessions to address synthetic compounds and high-potency variants. The federal government has similarly begun targeting specific high-potency and synthetic kratom compounds while maintaining a lighter regulatory touch on traditional botanical forms of the substance.

The kratom market has undergone significant transformation as manufacturers increasingly concentrate and chemically modify the plant's active compounds. While traditional kratom leaf has circulated as a largely unregulated herbal supplement for years, the emergence of potent derivatives like 7-hydroxymitragynine represents a new category of products that regulators struggle to address. Recent incidents, including deaths in Mississippi tied to concentrated kratom products, have galvanized legislative attention and created urgency around policy development.

The patchwork regulatory landscape reflects states' attempts to balance competing interests. Many jurisdictions seek to preserve consumer access to botanical kratom while restricting synthetic variants and high-potency extracts. Federal regulators have adopted a comparable framework, distinguishing between traditional forms and chemically enhanced versions. This bifurcated approach requires lawmakers to establish technical definitions and potency thresholds that effectively separate products while remaining administratively feasible.